Friday, October 7, 2022
HomeTechnologyA Self-Amplifying Nanodrug to Manipulate Janus-Faced Nature of Ferroptosis for Tumor Therapy

A Self-Amplifying Nanodrug to Manipulate Janus-Faced Nature of Ferroptosis for Tumor Therapy

Ferroptosis, an unusual nonapoptotic cell death caused by iron-dependent accumulation of lipid peroxide, enables flexible design of antitumor platform. Specifically, as a positive role, ferroptosis can induce immune response accompanied with the interferon-γ (IFN-γ)-triggered disruption of the glutathione peroxidase 4 pathway for cascade enhancement of ferroptotic cell death and ferroptosis-induced immunotherapeutic efficacy. However, as a negative role, ferroptosis also triggers inflammation-associated immunosuppression by up-regulation of cyclooxygenase-2/prostaglandin E2 pathway and IFN-γ-associated adaptive immune resistance by up-regulation of programmed death ligand-1 (PD-L1), impeding the antitumor efficacy of multiple immune cells by immune escape. Negative and positive roles endow ferroptosis with janus-faced nature. It is urgent to manipulate the janus-faced nature of ferroptosis for eliciting the maximized ferroptotic therapeutic efficacy. Herein, a self-amplifying nanodrug (RCH NPs) was designed by co-assembling hemin (ferric porphyrin), celecoxib (anti-inflammatory drug) and roscovitine (cyclin-dependent kinase 5 inhibitor) with the assistance of human serum albumin for reprograming janus-faced nature of ferroptosis. During hemin-triggered ferroptosis, celecoxib disrupted the inflammation-related immunosuppression while roscovitine destroyed IFN-γ-induced up-regulation of PD-L1 by genetic blockade effect. The RCH NPs thus demonstrated superior therapeutic effects on tumors, thanks to the self-amplifying ferroptotic immunotherapy. Our work offers a conceptually innovative strategy for harnessing ferroptosis against tumors.



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments